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Background: COVID-19, caused by the virus SARS-CoV-2, has brought extensive challenges to the scientific community in
recent months. Several studies have been undertaken in an attempt to minimize the impact of the disease worldwide. Although
new knowledge has been quickly disseminated, including viral mechanisms, pathophysiology, and clinical findings, there is a
lack of information on the effective pharmacological management of this disease. In vitro studies have shown some benefits
related to the use of antimalarials (chloroquine and hydroxychloroquine) for inhibiting SARS-CoV-2. However, the data from
open clinical trials on COVID-19 patients are controversial.
Objective: We present the protocol for a research project that compares the potential protective effect of antimalarials in
preventing moderate-to-severe forms of COVID-19 in two groups: (1) patients treated chronically with antimalarials for rheumatic
diseases and (2) other members of the patients’ household who have not been diagnosed with rheumatic diseases and are not
taking antimalarials.
Methods: This is a 24-week, prospective, observational cohort study comprising patients from public and private health services
across Brazil, who chronically use antimalarials for the treatment of immune-mediated rheumatic diseases, osteoarthritis, or
chikungunya-related arthropathy. A total of six sequential phone interviews were scheduled during the COVID-19 outbreak in
five different regions of Brazil. Information regarding social, epidemiological, and demographic data, as well as details about
rheumatic diseases, antimalarials, comorbidities, and concomitant medication, is being recorded using a specific online form in
the REDCap database. Symptoms suggestive of COVID-19, including fever, cough, dyspnea, anosmia, and dysgeusia, are being
self-reported and collected via phone interviews. Our main outcomes are hospitalization, need of intensive care unit, and death.
Results: Recruitment began at the end of March 2020, and the inclusion was done during an 8-week period (from March 29 to
May 17) with a total of 10,443 individuals enrolled at baseline, 5166 of whom have rheumatic diseases, from 23 tertiary
rheumatology centers across 97 Brazilian cities. Data analysis is scheduled to begin after all inclusion data have been collected.
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Conclusions: This study, which includes a large sample of chronic antimalarial users, will allow us to explore whether
SARS-CoV-2 infection may be associated with immune-mediated rheumatic diseases and long-term antimalarial usage.
Trial Registration: Brazilian Registry of Clinical Trials RBR–9KTWX6; http://www.ensaiosclinicos.gov.br/rg/RBR-9ktwx6/
International Registered Report Identifier (IRRID): DERR1-10.2196/23532
(JMIR Res Protoc 2020;9(10):e23532) doi: 10.2196/23532
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Introduction
COVID-19, which originated from Wuhan, China, in December
2019, remains a major challenge for scientists and the medical
community as it continues to spread rapidly across the world
[1,2]. The rapid transmission of the disease, which is caused by
the novel coronavirus SARS-CoV-2, and the need to minimize
its impact have caused scientific research and information to
emerge at a record speed, but there are still numerous knowledge
gaps [3-6].
In recent months, a marked information revolution has been
observed, relating to viral mechanisms, pathophysiology, and
heterogeneous clinical findings with different severity grades.
Those infected with COVID-19 range from asymptomatic
individuals to critically ill patients with outcomes like severe
acute respiratory syndrome, coagulopathy (a prothrombotic
state triggered by inflammation and other factors), and death
[7-13]. Age and concomitant diseases, especially hypertension,
diabetes, and heart, kidney, and lung diseases, are associated
with poor outcomes [14-18].
Considering there is no specific, effective pharmacological
treatment for COVID-19, several drugs have been tested, such
as antivirals (lopinavir-ritonavir, remdesivir, favipiravir);
antimalarials alone or combined with azithromycine; interleukin
6 (IL-6) antagonists; Janus kinase inhibitors and interferon, as
well as other procedures (extracorporeal membrane oxygenation
and convalescent plasma). However, to date, there are no data
on the potential preventive effect of any of these, regardless of
timing (pre-exposure, symptomatic period, or inflammatory
phase) [19-27].
The role of chloroquine and hydroxychloroquine in treating
patients with malaria and immune-mediated rheumatic diseases
(IMRD) is well-known, especially in cases of systemic lupus
erythematous and rheumatoid arthritis. In vitro studies have
shown antimalarials have an antiviral effect against some
viruses, such as SARS-CoV (severe acute respiratory
syndrome–associated coronavirus), MERS-CoV (Middle East
respiratory syndrome coronavirus), SARS-CoV-2, HIV, Zika,
and influenza A(H5N1), especially in relation to endosomal
membrane pH changes and an inhibitory mechanism to hamper
the viral entry inside the cells. However, clinical trials are
controversial and present many methodological problems,
including randomization, dosage, time of use, endpoint
definitions, outcomes, and safety issues [28-35].
Among rheumatologists, antimalarials have been used safely
and effectively for several decades in patients with rheumatic
diseases [36]. For this reason, rheumatologists and rheumatic
patients who are long-term users of antimalarials were involved
in COVID-19–related discussions and research [37-39]. Our
main hypothesis is that patients with rheumatic diseases who
chronically use antimalarials could have a lower rate of
moderate-to-severe forms of COVID-19 since these drugs work
as immune modulators in mitigating cytokine storm and poor
prognosis.
Objectives
Our primary aim is to assess the potential preventive effects of
antimalarials in reducing the incidence of moderate-to-severe
forms of COVID-19 in patients with rheumatic diseases.
Secondarily, we aim to determine the frequency of SARS-CoV-2
infection in patients with rheumatic diseases who are chronic
users of antimalarials. For both objectives, patients with
rheumatic diseases will be compared with members of their
household who are not taking antimalarials.
Methods
Design
The study design will be a prospective, multicentric,
observational cohort study with a control group.
Sample Size
Considering a moderate-to-severe COVID-19 rate as the
dependent variable, a rate which the current literature estimates
to be 20% [4,6,10-18,40-42] as well as the proportion of 1 case
for every 2 controls, the sample calculation was approximately
3000 antimalarial users and 6000 nonusers, with an error α=5%
and β=20%.
Inclusion Criteria
The inclusion criteria are as follows:
• Men and women;
• >18 years of age;
• Use of antimalarials for at least 30 days before inclusion
in the study;
• Diagnosis of IMRD (according to the criteria of the
American College of Rheumatology or European League
Against Rheumatism), rheumatoid arthritis [43], systemic
lupus erythematosus [44], Sjögren's syndrome [45],
systemic sclerosis [46], inflammatory myopathies [47], and
mixed connective tissue disease [48];
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• Diagnosis of osteoarthritis (subgroup) [49];
• Diagnosis of chikungunya-related arthropathy (subgroup).
Exclusion Criteria
The exclusion criteria, which apply to both patients and controls,
are as follows:
• Previous use of chloroquine or equivalent that was not in
the past 6 months;
• History of solid organ or bone marrow transplantation;
• Neoplasm of solid organs or lymphatic or myeloproliferative
lineage in the past 12 months with or without adjuvant
chemotherapy;
• Positive HIV status, regardless of highly active antiretroviral
therapy;
• Use of intravenous human immunoglobulin in the past 30
days;
• End-stage renal disease on peritoneal dialysis and
hemodialysis.
Control Group
The control group will consist of healthy individuals aged >18
years, who are household cohabitants or work colleagues of
patients with rheumatic diseases in the intervention group.
Contact with a suspected or confirmed case of COVID-19 is
defined as an individual sharing accommodations with a patient
with a rheumatic disease (eg, residing in the same house or
environment as roommates, occupational colleagues, etc). The
exposure grade assessment is individualized, considering the
type of environment and the exposure time.
For each case, two household and/or professional contact
individuals will be selected as controls. The choice of the first
control is prioritized by flu-like symptoms and defined as the
“symptomatic group,” including suspected or confirmed cases.
Those without symptoms will comprise the “asymptomatic
group;” both household and/or contact individuals can be
selected, preferably paired for age and sex.
The household and/or workplace contacts were chosen to
characterize the control group because of their high
epidemiological value during community viral transmissions
worldwide, instead of including nonusers of antimalarials with
rheumatic diseases. Moreover, lupus patients without
antimalarial treatment are quite uncommon, except in those
with previous toxicity (maculopathy, allergy, long-term
remission, etc).
Data Collection
Data are being collected regarding social, epidemiological, and
demographic characteristics, as well as detailed information on
antimalarials (type of salt, dosage, frequency, adherence during
the pandemic) and rheumatic disease (diagnosis, disease
activity). In addition, aspects related to comorbidities, smoking,
alcohol intake, and concomitant medications are being recorded,
as well as specific information about COVID-19 symptoms and
main outcomes (hospitalization, need for intensive care unit,
and death) in both groups (Multimedia Appendix 1).
All phone interviews are being conducted by health care
professionals (eg, volunteer medical students), all previously
trained by the principal investigator or subinvestigator from
each rheumatology center (Figure 1). This training included a
tutorial in PDF and video formats about each step of the study
protocol. In addition, several WhatsApp-based groups were
formed and supervised by the principal investigator,
subinvestigator, or study coordinators to find the best solution
for minimizing eventual problems.
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Figure 1. Centers participating in the study.
All patients and controls gave a verbal informed consent before
participating in this cohort study. The need for signed informed
consent was waived by the Brazilian National Ethics Committee
(CONEP) due to the urgency of the pandemic. However, it is
worth emphasizing that participation was voluntary for both
groups. Research subjects will not be identified by their full
name at any time and will not have their personal data disclosed.
The data are being stored on the REDCap platform, with
telephone interviews performed as shown in Figure 2. Interviews
with patients with invalid contact information or who did not
answer the telephone after three consecutive calls at intervals
of 3 days were canceled, although patients were not removed
from the study. All patients will be evaluated during the closing
visit (V6), unless they decline to participate, regardless of
whether intermediary visits were missed (V2 to V5).
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Figure 2. Telephone interview schedule.
A clinically confirmed case of COVID-19 was defined according
to the Brazilian Ministry of Health criteria [50] that included
self-reported symptoms (fever, cough, nasal congestion,
shortness of breath, malaise, myalgia, decline in general
condition, and sudden anosmia and/or dysgeusia) and/or have
been in contact with someone with a confirmed or suspected
case of COVID-19. A positive PCR (polymerase chain reaction)
test for SARS-CoV-2, via oropharyngeal and nasopharyngeal
sampling or a specific confirmatory serology (immunoglobulin
G and/or immunoglobulin M), is needed to test for infection,
according to the Brazilian Ministry of Health [50] (Figure 3).
Figure 3. Suspected vs confirmed cases of COVID-19. RT-PCR: real-time polymerase chain reaction, IgM: immunoglobulin M, IgA: immunoglobulin
A, IgG: immunoglobulin G, ELISA: enzyme-linked immunosorbent assay, IC: ion channel, ECLIA: electrochemiluminescence immunoassay.
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Moderate-to-severe cases are defined as those that require
hospitalization, mechanical ventilation, or result in death.
Through direct contact with hospitals, hospitalized patients are
being clinically evaluated in terms of longitudinal follow-up
and treatment outcome, infection severity, length of stay, need
for intensive care, mechanical ventilation, and cause of death.
Considering the heterogeneous community viral transmission
in Brazil, some epidemiological approaches were developed to
assure a similar path involving patients with rheumatic diseases
and controls, such as the same pandemic COVID-19 curve in
each city and region [41]. Therefore, after initial contact (V1),
two strategies were adopted to maintain the follow-up of patients
and to optimize the capture of main outcomes. Firstly, an active
strategy is addressed in cases of flu-like syndrome and
symptoms suggestive of COVID-19. For this strategy, the patient
or household member is shown how to provide clinical data on
the patient or his/her control through a toll-free telephone
number (the 0800 system). Secondly, the patient is contacted
every week by the REDCap team to gather relevant data on
infection. An additional visit is conducted if the patient or
control provides information about flu symptoms or disease
activity via an unscheduled phone call or contact through the
toll-free number. In both cases the individual will be advised
to stay home and use painkillers or an antipyretic. In case of
worsening/severe symptoms (eg, persistent cough or fever and
shortness of breath), they will be advised to visit a hospital or
to make an appointment with a physician involved in our study.
Outcomes
Primary outcomes (at baseline and during the 24-week study
period) are as follows:




• Need for intensive care unit
• Need for mechanical ventilation
• Total hospitalization time
• Date of occurrence of an adverse event (eg, death,
hospitalization)
Secondary outcomes are as follows:
• General clinical differences in COVID-19 course severity
between rheumatic patients and nonrheumatic controls;
• Initial clinical differences and progression to moderate or
severe course of disease between the two groups.
Confounding and adjustment variables are age, sex,
comorbidities, concomitant medications, and flu vaccine.
Ethics
This project was registered with the Brazilian Registry of
Clinical Trials (ID RBR-9KTWX6).
The project, which is currently in the data collection phase, was
approved by the Brazilian Committee of Ethics in Human
Research–CONEP (CAAE 30246120.3.1001.5505).
Statistical Analysis
The data will be analyzed using descriptive statistics—absolute
and relative frequencies for categorical variables and quantitative
measures (mean, quartiles, minimum, maximum, and standard
deviation) for numerical variables. The normality of the data
will be verified using the Kolmogorov-Smirnov test.
A chi-square test will be used to assess the association between
categorical variables with standardized adjusted residual
calculation; Fisher exact test will be used for small samples.
The linear associations between two variables of a numerical
nature will be evaluated using Pearson correlation.
To evaluate the behavior of clinical variables between two points
in time by group, analysis of variance (ANOVA) will be used,
with repeated measures. In the case of nonnormality of data,
the means of the groups at each time point will be compared
using the Kruskal-Wallis nonparametric test. To compare the
means between phone visits in each group, the Wilcoxon
nonparametric test will be used.
The comparison between the means of numerical variables with
normal distribution will be verified through the Student t test.
If the assumption of normality is violated, the Mann-Whitney
nonparametric test will be used.
Adjusted multiple linear regression models will be used to assess
the simultaneous effects of sex, age, duration of illness,
comorbidities, concomitant medications, and other confounding
variables, according to group and predefined outcomes. For
dichotomous dependent variables, a logistic regression model
will be preferred. Survival analysis models, including log rank
and Kaplan-Meier tests, adjusted for confounding variables,
will be developed to assess the main outcomes over time. The
time defined as the end date will be the date of a major event,
such as illness with confirmation or suspicion of infection,
hospitalization, or death.
Correlation analysis will be performed using the Pearson test
to assess the relationship between the incidence rate of
confirmed COVID-19 cases per 100,000 inhabitants and the
proportion of symptomatic patients and controls in
municipalities. Data of confirmed cases per municipality are
available through the Brasil.io project [51]. The QGIGS Desktop
3.6.0 (Open Source Geospatial Foundation) will be used for
map plotting.
SPSS, version 20 (IMB Corp) will be used in all analyses, and
a P value <.05 will be considered significant.
Results
This study is in the data collection phase. Study recruitment
opened in March 2020. In an 8-week period (from March 29 to
May 17), a total of 10,443 individuals enrolled at baseline
(including 5166 patients with rheumatic diseases) from 23
tertiary rheumatology centers in 97 Brazilian cities. Data
analysis is scheduled to start after all relevant data have been
collected.
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This study’s novel design, with its large sample of chronic
antimalarial users, will enable us to perform a thorough
prospective assessment (every 2 weeks) to explore whether
vulnerability to SARS-CoV-2 infection may be associated with
IMRD or to hydroxychloroquine after adjustments for
cofounders, especially those related to other immunosuppressive
drugs and comorbidities. On the other hand, it has some
limitations, such as compliance and adherence; a potential
shortage of HCQ (hydroxychloroquine) in some parts of our
country; possible biases associated with recalling symptoms;
inability to answer the phone (due to hospitalization or death),
and lack of confirmatory tests (PCR tests for SARS-CoV-2 or
antibody-based RNA [ribonucleic acid]) for all enrolled patients
and controls, especially in those with nonsevere forms. Future
randomized controlled trials may provide a better understanding
of these differences.
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